Praluent

Federal judge rules in favor of Sanofi, Regeneron in patent suit over cholesterol drugs

The decision was a loss for Amgen, which had claimed that Sanofi and Regeneron's drug Praluent infringed on its patents for the drug Repatha.

By Alaric DeArment

BioPharma, Policy

Amgen drops price of cholesterol-lowering drug Repatha by 60 percent

Equity research analysts wrote in a note Thursday that the move could have a beneficial read-across to another drug that has the same target as Repatha.

By Alaric DeArment

Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork

By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®

Closing the Quality-Affordability Gap in Workplace Mental Health

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

By Stephanie Baum

The Healthcare Payments Industry Faces a Perception Challenge

Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.

By Lisa Brooks, Vice President, Healthcare Partnerships